Guchelaar HJ - Search Results

1

Aberrant CYP2D6 metabolizer phenotypes do not show increased frequency in patients undergoing ECT after antidepressant therapy.

Mirzakhani H, van Dormolen J, van der Weide K, Guchelaar HJ, van Noorden MS, Swen J. Mirzakhani H, et al. Among authors: guchelaar hj. Pharmacogenet Genomics. 2015 Oct;25(10):515-7. doi: 10.1097/FPC.0000000000000167. Pharmacogenet Genomics. 2015. PMID: 26230381

2

Translating pharmacogenomics: challenges on the road to the clinic.

Swen JJ, Huizinga TW, Gelderblom H, de Vries EG, Assendelft WJ, Kirchheiner J, Guchelaar HJ. Swen JJ, et al. Among authors: guchelaar hj. PLoS Med. 2007 Aug;4(8):e209. doi: 10.1371/journal.pmed.0040209. PLoS Med. 2007. PMID: 17696640 Free PMC article. Review.

3

Use of plasmid-derived external quality control samples in pharmacogenetic testing.

van der Straaten T, Swen J, Baak-Pablo R, Guchelaar HJ. van der Straaten T, et al. Among authors: guchelaar hj. Pharmacogenomics. 2008 Sep;9(9):1261-6. doi: 10.2217/14622416.9.9.1261. Pharmacogenomics. 2008. PMID: 18781854 Review.

4

Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.

Dezentjé VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H. Dezentjé VO, et al. Among authors: guchelaar hj. Clin Cancer Res. 2009 Jan 1;15(1):15-21. doi: 10.1158/1078-0432.CCR-08-2006. Clin Cancer Res. 2009. PMID: 19118028 Review.

5

Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.

Dezentjé VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK, Egberts AC, Nortier JW, Guchelaar HJ. Dezentjé VO, et al. Among authors: guchelaar hj. J Clin Oncol. 2010 May 10;28(14):2423-9. doi: 10.1200/JCO.2009.25.0894. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385997

6

Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus.

Swen JJ, Wessels JA, Krabben A, Assendelft WJ, Guchelaar HJ. Swen JJ, et al. Among authors: guchelaar hj. Pharmacogenomics. 2010 Nov;11(11):1517-23. doi: 10.2217/pgs.10.121. Pharmacogenomics. 2010. PMID: 21121772

7

Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment.

Swen JJ, Guchelaar HJ, Baak-Pablo RF, Assendelft WJ, Wessels JA. Swen JJ, et al. Among authors: guchelaar hj. Pharmacogenet Genomics. 2011 Aug;21(8):461-8. doi: 10.1097/FPC.0b013e3283478173. Pharmacogenet Genomics. 2011. PMID: 21633322

8

Comment: global formulary review: how do we integrate pharmacogenomic information?

Swen JJ, Guchelaar HJ. Swen JJ, et al. Among authors: guchelaar hj. Ann Pharmacother. 2011 Jul;45(7-8):1030; author reply 1030-1. doi: 10.1345/aph.1P557a. Epub 2011 Jul 20. Ann Pharmacother. 2011. PMID: 21775697 No abstract available.

9

Alternative methods to a TaqMan assay to detect a tri-allelic single nucleotide polymorphism rs757210 in the HNF1β gene.

Swen JJ, Baak-Pablo RF, Guchelaar HJ, van der Straaten T. Swen JJ, et al. Among authors: guchelaar hj. Clin Chem Lab Med. 2011 Oct 21;50(2):279-84. doi: 10.1515/CCLM.2011.758. Clin Chem Lab Med. 2011. PMID: 22022982

10

The challenges of developing a 'medical-grade' genome.

van der Straaten T, Guchelaar HJ, Swen JJ. van der Straaten T, et al. Among authors: guchelaar hj. Pharmacogenomics. 2012 Mar;13(4):369-72. doi: 10.2217/pgs.12.6. Pharmacogenomics. 2012. PMID: 22379992 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

472 results

Search Page

Filters